ACAD
39.46
-0.39
-0.98%
AEMD
3.881
+0.001
+0.0309%
APRI
2.945
-0.205
-6.5206%
ARNA
1.53
-0.04
-2.55%
ATEC
3.41
-0.16
-4.48%
CNAT
4.86
-0.19
-3.76%
CRXM
0.23
+0.02
+7.23%
CYTX
1.73
-0.02
-1.14%
DXCM
77.805
-1.405
-1.774%
GNMK
11.36
-0.23
-1.98%
HALO
12.71
-0.16
-1.24%
ILMN
167.782
+0.962
+0.577%
INNV
0.16
0.00
+3.23%
INO
7.01
-0.16
-2.23%
ISCO
1.15
+0.05
+4.55%
ISIS
57.56
0.00
0.00%
LGND
106.33
-1.05
-0.98%
LPTN
2.93
0.00
0.00%
MBVX
3
-0.09
-2.91%
MEIP
1.69
-0.02
-1.17%
MNOV
6.49
+0.04
+0.62%
MRTX
5.65
-0.3
-5.04%
MSTX
0.114
-0.004
-3.4043%
NBIX
44.63
-0.5
-1.11%
NUVA
74.93
-0.04
-0.05%
ONCS
1.44
-0.02
-1.37%
ONVO
3.185
-0.015
-0.469%
OREX
4.485
-0.175
-3.755%
OTIC
15
-0.55
-3.54%
QDEL
21.5
-0.39
-1.78%
RCPT
231.96
0.00
0.00%
RGLS
1
-0.05
-4.76%
RMD
71.98
-0.04
-0.06%
SPHS
2.66
+0.01
+0.38%
SRNE
5.225
-0.125
-2.336%
TROV
1.975
-0.025
-1.250%
VICL
2.18
-0.01
-0.46%
VOLC
18
0.00
0.00%
ZGNX
10.451
-0.15
-1.4104%
ACAD
39.46
-0.39
-0.98%
AEMD
3.881
+0.001
+0.0309%
APRI
2.945
-0.205
-6.5206%
ARNA
1.53
-0.04
-2.55%
ATEC
3.41
-0.16
-4.48%
CNAT
4.86
-0.19
-3.76%
CRXM
0.23
+0.02
+7.23%
CYTX
1.73
-0.02
-1.14%
DXCM
77.805
-1.405
-1.774%
GNMK
11.36
-0.23
-1.98%
HALO
12.71
-0.16
-1.24%
ILMN
167.782
+0.962
+0.577%
INNV
0.16
0.00
+3.23%
INO
7.01
-0.16
-2.23%
ISCO
1.15
+0.05
+4.55%
ISIS
57.56
0.00
0.00%
LGND
106.33
-1.05
-0.98%
LPTN
2.93
0.00
0.00%
MBVX
3
-0.09
-2.91%
MEIP
1.69
-0.02
-1.17%
MNOV
6.49
+0.04
+0.62%
MRTX
5.65
-0.3
-5.04%
MSTX
0.114
-0.004
-3.4043%
NBIX
44.63
-0.5
-1.11%
NUVA
74.93
-0.04
-0.05%
ONCS
1.44
-0.02
-1.37%
ONVO
3.185
-0.015
-0.469%
OREX
4.485
-0.175
-3.755%
OTIC
15
-0.55
-3.54%
QDEL
21.5
-0.39
-1.78%
RCPT
231.96
0.00
0.00%
RGLS
1
-0.05
-4.76%
RMD
71.98
-0.04
-0.06%
SPHS
2.66
+0.01
+0.38%
SRNE
5.225
-0.125
-2.336%
TROV
1.975
-0.025
-1.250%
VICL
2.18
-0.01
-0.46%
VOLC
18
0.00
0.00%
ZGNX
10.451
-0.15
-1.4104%
Home » Archive by Category

Syndication

Natera Inc. Announces Fourth Quarter and Fiscal Year 2016 Earnings Conference Call

February 28, 2017 – 5:00 am

SAN CARLOS, Calif., Feb. 28, 2017 /PRNewswire/ — Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2016 after the market close on March 7, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.

Conference Call Information:

Event:            

Natera’s Fourth Quarter and Year End 2016 Financial Results Conference Call

Date:           

March 7, 2017

Time:                   

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In:            

(877) 823-0171, Domestic

(617) 500-6932, International

Conference ID:        

77689151

Webcast:            

investor.natera.com  

A webcast replay will be available at investor.natera.com.

About Natera
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system.

Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier test to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to detect for common chromosomal anomalies in a fetus as early as nine weeks of gestation.

Each test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test.

These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.  

Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit http://www.natera.com and connect on Twitter and Facebook.

Contacts:

Natera, Inc.

Mike Brophy, Chief Financial Officer, 650-249-9091 x1471

mbrophy@natera.com

Laura Zobkiw, Corporate and Media Relations, 650-249-9091 x1649

Lzobkiw@natera.com

 

SOURCE Natera

Trovagene to Attend the 29th Annual ROTH Conference

February 28, 2017 – 5:00 am

SAN DIEGO, Feb. 28, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, is scheduled to attend the 29th Annual ROTH Conference, March 12-15, 2017, at the Ritz Carlton Laguna Niguel in Dana Point, CA. 

Bill Welch, Chief Executive Officer, and Mark Erlander, Chief Scientific Officer, will be attending the conference and participating in investor meetings on March 13th and 14th. No formal presentation is being made.

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in an effort to enable itself, through its CLIA/CAP – accredited laboratory, and others, through the distribution of research use only (RUO) kits and systems, to detect and monitor ctDNA in urine and blood. The Company’s PCM technology allows for detection and quantitation of oncogene mutations in cancer patients for improved disease management. Trovagene’s TroveraTM liquid biopsy test, which utilizes PCM technology, is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property, including multiple issued patents and pending patent applications worldwide. For more information, please visit http://www.trovagene.com/.

Trovagene Contact:

Vicki Kelemen
Sr. Director, Marketing Communications
858-952-7652
vkelemen@trovagene.com

 

SOURCE Trovagene, Inc.

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results

February 28, 2017 – 4:30 am

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2016 financial results after market close on Tuesday, March 7, 2017.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results.

Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 75337580.  The conference call will also be webcast live and can be accessed from Rigel’s website at www.rigel.com. The webcast will be archived and available for replay after the call via the Rigel website.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s current clinical programs include clinical studies of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor in a number of indications. The company completed and reported results from the FIT Phase 3 clinical program of fostamatinib in chronic immune thrombocytopenia (ITP). Rigel is also conducting a Phase 2 clinical study with fostamatinib in autoimmune hemolytic anemia (AIHA) and a Phase 2 clinical study for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in development with partners BerGenBio AS (Phase 2) and Daiichi Sankyo (Phase 1).

Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com

Media Contact: Jessica Daitch, Inventiv Health PR Group
Phone: 917.816.6712
Email: Jessica.daitch@inventivhealth.com

 

 

SOURCE Rigel Pharmaceuticals, Inc.

Viking Therapeutics to Present at Upcoming Investor Conferences

February 28, 2017 – 4:30 am

SAN DIEGO, Feb. 28, 2017 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in two upcoming investor conferences.  Dr. Lian will deliver a corporate presentation and participate in two panel discussions at the Maxim Group Inaugural Healthcare Investor and Partnering Conference in Shanghai, China, being held March 6 – 7, 2017.  Dr. Lian will also present at the 29th Annual Roth Conference in Dana Point, California, being held March 12 – 15, 2017. 

Details of these presentations and panels are as follows:

Maxim Group Inaugural Healthcare Investor and Partnering Conference, Shanghai, China

Panel: Chasing the Next Blockbuster

Time/Date:

Monday, March 6 at 1:40 PM CST

Location:

The Park Hyatt Shanghai

Presentation:

Time/Date:

Monday, March 6 at 2:45 PM CST

Location:

The Park Hyatt Shanghai

Panel: Establishing POC Data for Unmet Medical Needs

Time/Date:

Tuesday, March 7 at 3:20 PM CST

Location:

The Park Hyatt Shanghai

29th Annual Roth Conference, Dana Point, California

Time/Date:

Monday, March 13 at 7:00 AM PT

Location:

Ritz Carlton Laguna Niguel

Room:

Yellow – Salon 6

 

To access the live webcast of Viking’s presentation at the 29th Annual Roth Conference, please visit “Webcasts & Presentations” within the News & Events section of Viking’s Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives.  Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.  The company’s clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist in Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.  Viking also plans to initiate a proof-of-concept study of VK2809 in patients with glycogen storage disease type Ia.  The company is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.

Follow Viking on Twitter @Viking_VKTX.

 

SOURCE Viking Therapeutics, Inc.

Staff Analyst – Sayva Solutions – San Diego, CA

February 27, 2017 – 11:57 pm

Strong attention to detail. Publicly traded, growing biotech company looking for a Staff Analyst to assist with GL accounting, financial planning, inventory and…From Sayva Solutions – Tue, 28 Feb 2017 07:57:28 GMT – View all San Diego jobs

Principal Data Manager (US Regional – Home-based) – Premier Research – San Diego, CA

February 27, 2017 – 10:55 pm

Reviewing draft protocols and CRFs for potential data collection and representation, database structure or data entry problems, and provides feedback to the…From Premier Research – Tue, 28 Feb 2017 06:55:42 GMT – View all San Diego jobs

Quality Assurance Assistant (San Diego)

February 27, 2017 – 7:39 pm

Job Description: Ideal candidate will have BS degree with at least 1-3 years of experience working in a QA or admin capacity. Seeking an individual to assist in product documentation, raw material analysis/release, CAPA & NCMR Systems Work Environmen […]

Buyer – Biolegend – San Diego, CA

February 27, 2017 – 7:31 pm

Prior experience in life science, biotechnology or pharmaceutical environment. BioLegend develops world-class, cutting-edge antibodies and reagents for…From Biolegend – Tue, 28 Feb 2017 03:31:08 GMT – View all San Diego jobs

Research Associate – Job Opportunity (San Diego)

February 27, 2017 – 4:25 pm

Kelly Scientific is seeking Research Associates. We have a number of open positions with our clients in San Diego. Seeking candidates with experience in ELISA, cell culture, PCR, and chemistry. Degree in a life science required. Local candidates only […

Supervisor, Production – Illumina, Inc. – San Diego, CA

February 27, 2017 – 4:12 pm

The Production Supervisor will directly manage the technicians and operators on this high throughput (and high rate of change) biotechnology production line….From Illumina, Inc. – Tue, 28 Feb 2017 00:12:14 GMT – View all San Diego jobs